{"url":"https://newsforagent.com/news/2026-11-22/fosun-pharma-a-share-buyback-plan","markdown_url":"https://newsforagent.com/news/2026-11-22/fosun-pharma-a-share-buyback-plan.md","title":"Fosun Pharma Plans A-Share Buyback of Up to 500 Million Yuan","headline":"Shanghai Fosun Pharmaceutical Plans A-Share Buyback Worth 250-500 Million Yuan","description":"Fosun Pharma plans to buy back A-shares worth 250-500 million yuan, following a chairman's proposal days earlier and a HK$1 billion H-share repurchase in September.","section":"Dividends & Buybacks","published_at":"2026-11-22T10:20:08+00:00","modified_at":"2026-11-22T10:20:08+00:00","author":"News Desk","key_takeaways":["Fosun Pharma plans to buy back A-shares worth 250-500 million yuan, or about $37.44-74.88 million.","Chairman Chen Qiyu proposed an A-share buyback of 250-500 million yuan on November 17, 2026.","Fosun Pharma announced a H-share repurchase plan of up to HK$1 billion in September 2026."],"companies":[{"name":"Fosun Pharma","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000084b/fosun-pharma","website":"http://www.fosunpharma.com"}],"source":{"publisher":"The future of trading","title":"Shanghai Fosun Pharmaceutical Plans A-Share Buyback","url":"https://capital.com/en-int/news/shanghai-fosun-pharmaceutical-plans-a-share-buyback"},"other_sources":[],"tags":["Dividends & Buybacks","Fosun Pharma"],"body_markdown":"Shanghai Fosun Pharmaceutical Group plans to buy back its A-shares for 250-500 million yuan, or about $37.44-74.88 million, the company said. [The future of trading](https://capital.com/en-int/news/shanghai-fosun-pharmaceutical-plans-a-share-buyback) published the announcement on November 22, 2026, citing a company statement.\n\n## Fosun Pharma's A-Share Buyback Plan\n\n[Fosun Pharma](https://akta.pro/company-profiles/000084b/fosun-pharma) is a Shanghai-headquartered, dual-listed pharmaceutical and healthcare group that develops innovative drugs, biosimilars, cell therapies and diagnostics for oncology, infectious disease and rare diseases across more than 90 countries. The company said it plans to repurchase A-shares valued at 250-500 million yuan. The announcement gave the range in yuan and in dollars at a rate of 6.6770 Chinese yuan renminbi per dollar.\n\nThe plan follows a proposal by the company's chairman. The November 22 announcement sets out the company's plan for the same yuan range.\n\n## Fosun Pharma's Earlier Buyback and Deal Record\n\nFosun Pharma announced a H-share repurchase plan of up to HK$1 billion in September 2026, funded by proceeds from selling about 6% of Gland Pharma for roughly $294 million, according to [company records](https://akta.pro/company-data) on akta.pro. The same records show 2025 annual operating revenue of RMB 416.62 billion, approximately $57.3 billion, and 2025 net profit attributable to shareholders after deducting non-recurring gains and losses of RMB 33.71 billion, up 21.69% year over year.\n\n## Drug Approvals and Trial Steps Before the Buyback\n\nOn November 16, 2026, subsidiary Xingrui Jingxuan received NMPA approval to conduct a clinical trial of SRT-003-1, a radiopharmaceutical for PET imaging of FAP-positive solid tumors, with a Phase I study in China planned once conditions are met, Moomoo reported. Fosun Pharma's holding subsidiary began Phase II clinical trials of FKC516 injection, Jiemian reported on November 12, 2026. Forbes reported on October 28, 2026 that Fosun Pharma's Q3 2026 net profit rose 15%, aided by one-off gains, with revenue up 1.4% to 10 billion yuan.\n\n## What Comes Next for the A-Share Buyback\n\nThe November 22 announcement states the buyback plan in yuan and dollars but gives no timetable for execution.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}